Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 11/2017

01-11-2017 | Retinal Disorders

Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy

Authors: Eui Chun Kang, Seonghee Choi, Hyoung Jun Koh

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 11/2017

Login to get access

Abstract

Purpose

To investigate predictive factors for changes in best-corrected visual acuity (BCVA) at 24 months after intravitreal ranibizumab (IVR) for neovascular age-related macular degeneration (nAMD).

Methods

This retrospective study included 55 eyes of 55 consecutive patients (32 men and 23 women) with nAMD who received three consecutive monthly IVR injections and were re-treated as needed over a 24-month period. We used the mean changes in logarithm of the minimal angle of resolution (logMAR) BCVA at 24 months as the dependent variable in regression analysis.

Results

The presence of intraretinal cystoid spaces in the inner nuclear layer (INLc, P = 0.004) and baseline subfoveal choroidal thickness (SFCT, P = 0.013) predicted BCVA changes from baseline to 24 months. The presence of INLc and thinning of SFCT were associated with decreased BCVA at 24 months. Thirty-five eyes without INLc showed improved logMAR BCVA, from 0.550 ± 0.273 to 0.368 ± 0.274 (P = 0.045); however, 20 eyes with INLc showed decreased logMAR BCVA, from 0.708 ± 0.347 to 0.971 ± 0.523 (P < 0.001) through the 24-month follow-up. The mean number of IVR injections during the follow-up period was 8.74 ± 4.76 in eyes without INLc and 10.63 ± 4.72 in eyes with INLc, without a statistically significant difference (P = 0.144).

Conclusion

Eyes with INLc or thinned SFCT showed worse visual outcomes compared with eyes without the INLc or with thick SFCT. Furthermore, eyes without INLc showed improved BCVA; however, eyes with INLc showed decreased BCVA with an as-needed regimen.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP (2003) Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48:257–293CrossRefPubMed Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP (2003) Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48:257–293CrossRefPubMed
2.
go back to reference Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AH (2013) Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res 37:182–199CrossRefPubMed Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AH (2013) Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res 37:182–199CrossRefPubMed
3.
go back to reference Wolf A, Kampik A (2014) Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol 252:647–655CrossRefPubMedPubMedCentral Wolf A, Kampik A (2014) Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol 252:647–655CrossRefPubMedPubMedCentral
4.
go back to reference Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379:1728–1738CrossRefPubMed Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379:1728–1738CrossRefPubMed
5.
go back to reference Miller JW (2013) Age-related macular degeneration revisited--piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Ophthalmol 155:1-35.e13 Miller JW (2013) Age-related macular degeneration revisited--piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Ophthalmol 155:1-35.e13
6.
go back to reference Kodjikian L, Decullier E, Souied EH, Girmens JF, Durand EE, Chapuis FR, Huot L (2014) Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials. Graefes Arch Clin Exp Ophthalmol 252:1529–1537CrossRefPubMedPubMedCentral Kodjikian L, Decullier E, Souied EH, Girmens JF, Durand EE, Chapuis FR, Huot L (2014) Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials. Graefes Arch Clin Exp Ophthalmol 252:1529–1537CrossRefPubMedPubMedCentral
7.
go back to reference Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382:1258–1267CrossRefPubMed Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382:1258–1267CrossRefPubMed
8.
go back to reference Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398CrossRefPubMedPubMedCentral Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398CrossRefPubMedPubMedCentral
9.
go back to reference Berg K, Pedersen TR, Sandvik L, Bragadottir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146–152CrossRefPubMed Berg K, Pedersen TR, Sandvik L, Bragadottir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146–152CrossRefPubMed
10.
go back to reference Spaide RF (2009) The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system. Am J Ophthalmol 148:1–3CrossRefPubMed Spaide RF (2009) The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system. Am J Ophthalmol 148:1–3CrossRefPubMed
11.
go back to reference Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, Fajnkuchen F, Tadayoni R (2011) Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 31:26–30CrossRefPubMed Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, Fajnkuchen F, Tadayoni R (2011) Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 31:26–30CrossRefPubMed
12.
go back to reference Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS (2015) A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol. doi:10.1136/bjophthalmol-2015-306987 Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS (2015) A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol. doi:10.​1136/​bjophthalmol-2015-306987
13.
go back to reference Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR (2015) Prospective trial of treat-and-extend versus monthly dosing for Neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122:2514–2522CrossRefPubMed Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR (2015) Prospective trial of treat-and-extend versus monthly dosing for Neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122:2514–2522CrossRefPubMed
14.
go back to reference Rayess N, Houston SK 3rd, Gupta OP, Ho AC, Regillo CD (2015) Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol 159:3–8.e1CrossRefPubMed Rayess N, Houston SK 3rd, Gupta OP, Ho AC, Regillo CD (2015) Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol 159:3–8.e1CrossRefPubMed
15.
go back to reference Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, Tamura H, Ooto S, Tsujikawa A, Yoshimura N (2015) Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology 122:2303–2310CrossRefPubMed Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, Tamura H, Ooto S, Tsujikawa A, Yoshimura N (2015) Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology 122:2303–2310CrossRefPubMed
16.
go back to reference Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG (2016) Outcomes in eyes with retinal Angiomatous proliferation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology 123:609–616CrossRefPubMed Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG (2016) Outcomes in eyes with retinal Angiomatous proliferation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology 123:609–616CrossRefPubMed
17.
go back to reference Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, Bejan-Angoulvant T (2014) Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol 132:1317–1326CrossRefPubMed Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, Bejan-Angoulvant T (2014) Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol 132:1317–1326CrossRefPubMed
18.
go back to reference Munk MR, Ceklic L, Ebneter A, Huf W, Wolf S, Zinkernagel MS (2016) Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol 94:e757–e764CrossRefPubMed Munk MR, Ceklic L, Ebneter A, Huf W, Wolf S, Zinkernagel MS (2016) Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol 94:e757–e764CrossRefPubMed
19.
go back to reference Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Mones J, Regillo C, Tadayoni R, Talks J, Wolf S (2015) TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: a literature review and consensus recommendations. Retina 35:1489–1506CrossRefPubMed Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Mones J, Regillo C, Tadayoni R, Talks J, Wolf S (2015) TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: a literature review and consensus recommendations. Retina 35:1489–1506CrossRefPubMed
20.
go back to reference Schmidt-Erfurth U, Waldstein SM (2016) A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res 50:1–24CrossRefPubMed Schmidt-Erfurth U, Waldstein SM (2016) A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res 50:1–24CrossRefPubMed
21.
go back to reference Sulzbacher F, Roberts P, Munk MR, Kaider A, Kroh ME, Sacu S, Schmidt-Erfurth U (2015) Relationship of retinal morphology and retinal sensitivity in the treatment of neovascular age-related macular degeneration using aflibercept. Invest Ophthalmol Vis Sci 56:1158–1167CrossRef Sulzbacher F, Roberts P, Munk MR, Kaider A, Kroh ME, Sacu S, Schmidt-Erfurth U (2015) Relationship of retinal morphology and retinal sensitivity in the treatment of neovascular age-related macular degeneration using aflibercept. Invest Ophthalmol Vis Sci 56:1158–1167CrossRef
22.
go back to reference Simader C, Ritter M, Bolz M, Deak GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM (2014) Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 121:1237–1245CrossRefPubMed Simader C, Ritter M, Bolz M, Deak GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM (2014) Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 121:1237–1245CrossRefPubMed
23.
go back to reference Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15–22CrossRefPubMed Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15–22CrossRefPubMed
24.
go back to reference Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C (2015) Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology 122:822–832CrossRefPubMed Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C (2015) Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology 122:822–832CrossRefPubMed
25.
go back to reference Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ (2016) Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology 123:865–875CrossRefPubMedPubMedCentral Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ (2016) Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology 123:865–875CrossRefPubMedPubMedCentral
26.
go back to reference Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U (2016) Predictive value of retinal morphology for visual acuity outcomes of different Ranibizumab treatment regimens for Neovascular AMD. Ophthalmology 123:60–69CrossRefPubMed Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U (2016) Predictive value of retinal morphology for visual acuity outcomes of different Ranibizumab treatment regimens for Neovascular AMD. Ophthalmology 123:60–69CrossRefPubMed
27.
go back to reference Antcliff RJ, Hussain AA, Marshall J (2001) Hydraulic conductivity of fixed retinal tissue after sequential excimer laser ablation: barriers limiting fluid distribution and implications for cystoid macular edema. Arch Ophthalmol 119:539–544CrossRefPubMed Antcliff RJ, Hussain AA, Marshall J (2001) Hydraulic conductivity of fixed retinal tissue after sequential excimer laser ablation: barriers limiting fluid distribution and implications for cystoid macular edema. Arch Ophthalmol 119:539–544CrossRefPubMed
28.
go back to reference Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:223–232CrossRefPubMed Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:223–232CrossRefPubMed
29.
30.
go back to reference Freund KB, Zweifel SA, Engelbert M (2010) Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 30:1333–1349CrossRefPubMed Freund KB, Zweifel SA, Engelbert M (2010) Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 30:1333–1349CrossRefPubMed
31.
go back to reference Biesemeier A, Taubitz T, Julien S, Yoeruek E, Schraermeyer U (2014) Choriocapillaris breakdown precedes retinal degeneration in age-related macular degeneration. Neurobiol Aging 35:2562–2573CrossRefPubMed Biesemeier A, Taubitz T, Julien S, Yoeruek E, Schraermeyer U (2014) Choriocapillaris breakdown precedes retinal degeneration in age-related macular degeneration. Neurobiol Aging 35:2562–2573CrossRefPubMed
32.
go back to reference Berenberg TL, Metelitsina TI, Madow B, Dai Y, Ying GS, Dupont JC, Grunwald L, Brucker AJ, Grunwald JE (2012) The association between drusen extent and foveolar choroidal blood flow in age-related macular degeneration. Retina 32:25–31CrossRefPubMedPubMedCentral Berenberg TL, Metelitsina TI, Madow B, Dai Y, Ying GS, Dupont JC, Grunwald L, Brucker AJ, Grunwald JE (2012) The association between drusen extent and foveolar choroidal blood flow in age-related macular degeneration. Retina 32:25–31CrossRefPubMedPubMedCentral
33.
go back to reference Whitmore SS, Sohn EH, Chirco KR, Drack AV, Stone EM, Tucker BA, Mullins RF (2015) Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog Retin Eye Res 45:1–29CrossRefPubMed Whitmore SS, Sohn EH, Chirco KR, Drack AV, Stone EM, Tucker BA, Mullins RF (2015) Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog Retin Eye Res 45:1–29CrossRefPubMed
34.
go back to reference Sohn EH, Khanna A, Tucker BA, Abramoff MD, Stone EM, Mullins RF (2014) Structural and biochemical analyses of choroidal thickness in human donor eyes. Invest Ophthalmol Vis Sci 55:1352–1360CrossRefPubMedPubMedCentral Sohn EH, Khanna A, Tucker BA, Abramoff MD, Stone EM, Mullins RF (2014) Structural and biochemical analyses of choroidal thickness in human donor eyes. Invest Ophthalmol Vis Sci 55:1352–1360CrossRefPubMedPubMedCentral
35.
go back to reference Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG (2013) Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 91:540–546CrossRefPubMed Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG (2013) Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 91:540–546CrossRefPubMed
36.
go back to reference Rakic JM, Leys A, Brie H, Denhaerynck K, Pacheco C, Vancayzeele S, Hermans C, Macdonald K, Abraham I (2013) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol 7:1849–1858PubMedPubMedCentral Rakic JM, Leys A, Brie H, Denhaerynck K, Pacheco C, Vancayzeele S, Hermans C, Macdonald K, Abraham I (2013) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol 7:1849–1858PubMedPubMedCentral
37.
go back to reference Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Quere S, Schneider V (2013) Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 33:474–481CrossRefPubMed Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Quere S, Schneider V (2013) Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 33:474–481CrossRefPubMed
38.
go back to reference Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, Bogumil T, Heah T, Sivaprasad S (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220–226CrossRefPubMed Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, Bogumil T, Heah T, Sivaprasad S (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220–226CrossRefPubMed
39.
go back to reference Tufail A, Xing W, Johnston R, Akerele T, McKibbin M, Downey L, Natha S, Chakravarthy U, Bailey C (2014) The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 121:1092–1101CrossRef Tufail A, Xing W, Johnston R, Akerele T, McKibbin M, Downey L, Natha S, Chakravarthy U, Bailey C (2014) The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 121:1092–1101CrossRef
40.
go back to reference Chong V (2016) Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond) 30:270–286CrossRef Chong V (2016) Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond) 30:270–286CrossRef
41.
go back to reference Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, Cheung CM (2016) Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res 53:107–139CrossRefPubMed Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, Cheung CM (2016) Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res 53:107–139CrossRefPubMed
Metadata
Title
Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy
Authors
Eui Chun Kang
Seonghee Choi
Hyoung Jun Koh
Publication date
01-11-2017
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 11/2017
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-017-3776-9

Other articles of this Issue 11/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2017 Go to the issue